On This episode of Stock Movers:

- Novo Nordisk won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its effort to defend its market share from rival Eli Lilly.

- Ryanair was fined more than €255 million ($300 million) by Italy’s antitrust watchdog for allegedly using an “abusive strategy” to thwart third-party travel agencies.

- Cevian Capital raises its total holding in Akzo Nobel NV to 10.15% from ~5%, according to a filing with the Dutch financial authority AFM.

On This episode of Stock Movers:
- Novo Nordisk won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its effort to defend its market share from rival Eli Lilly.
- Ryanair was fined more than &euro;255 million ($300 million) by Italy&rsquo;s antitrust watchdog for allegedly using an &ldquo;abusive strategy&rdquo; to thwart third-party travel agencies.
- Cevian Capital raises its total holding in Akzo Nobel NV to 10.15% from ~5%, according to a filing with the Dutch financial authority AFM.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for news on today's biggest winners and losers in the stock market.

Stock Movers

Novo Nordisk's Pill, Ryanair Fined, Akzonobel's Activist

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/71c43d02-8250-468d-ac3c-b3bc00a5cf02/transcript

Advertisement